Details for Patent: 8,349,840
✉ Email this page to a colleague
Which drugs does patent 8,349,840 protect, and when does it expire?
Patent 8,349,840 protects REXULTI and is included in one NDA.
This patent has thirty-six patent family members in twenty-nine countries.
Summary for Patent: 8,349,840
| Title: | Piperazine-substituted benzothiophenes for treatment of mental disorders |
| Abstract: | The present invention provides a heterocyclic compound represented by the general formula (1): The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety. ##STR00001## |
| Inventor(s): | Yamashita; Hiroshi (Tokushima, JP), Ito; Nobuaki (Tokushima, JP), Miyamura; Shin (Tokushima, JP), Oshima; Kunio (Tokushima, JP), Matsubara; Jun (Tokushima, JP), Kuroda; Hideaki (Tokushima, JP), Takahashi; Haruka (Tokushima, JP), Shimizu; Satoshi (Tokushima, JP), Tanaka; Tatsuyoshi (Tokushima, JP) |
| Assignee: | Otsuka Pharmaceutical Co., Ltd. (Tokyo, JP) |
| Application Number: | 12/970,690 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,349,840 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; Use; |
Drugs Protected by US Patent 8,349,840
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Otsuka | REXULTI | brexpiprazole | TABLET;ORAL | 205422-001 | Jul 10, 2015 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) | ⤷ Sign Up | ||
| Otsuka | REXULTI | brexpiprazole | TABLET;ORAL | 205422-002 | Jul 10, 2015 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) | ⤷ Sign Up | ||
| Otsuka | REXULTI | brexpiprazole | TABLET;ORAL | 205422-003 | Jul 10, 2015 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) | ⤷ Sign Up | ||
| Otsuka | REXULTI | brexpiprazole | TABLET;ORAL | 205422-004 | Jul 10, 2015 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) | ⤷ Sign Up | ||
| Otsuka | REXULTI | brexpiprazole | TABLET;ORAL | 205422-005 | Jul 10, 2015 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) | ⤷ Sign Up | ||
| Otsuka | REXULTI | brexpiprazole | TABLET;ORAL | 205422-006 | Jul 10, 2015 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,349,840
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| Japan | 2005-116698 | Apr 14, 2005 |
International Family Members for US Patent 8,349,840
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 1869025 | ⤷ Sign Up | 300946 | Netherlands | ⤷ Sign Up |
| European Patent Office | 1869025 | ⤷ Sign Up | 122018000088 | Germany | ⤷ Sign Up |
| European Patent Office | 1869025 | ⤷ Sign Up | PA2018509 | Lithuania | ⤷ Sign Up |
| European Patent Office | 1869025 | ⤷ Sign Up | CA 2018 00028 | Denmark | ⤷ Sign Up |
| European Patent Office | 1869025 | ⤷ Sign Up | LUC00086 | Luxembourg | ⤷ Sign Up |
| European Patent Office | 1869025 | ⤷ Sign Up | 32/2018 | Austria | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
